185 related articles for article (PubMed ID: 18538111)
1. A study of dose-proportionality in the pharmacokinetics of the oral direct renin inhibitor aliskiren in healthy subjects.
Limoges D; Dieterich HA; Yeh CM; Vaidyanathan S; Howard D; Dole WP
Int J Clin Pharmacol Ther; 2008 May; 46(5):252-8. PubMed ID: 18538111
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, safety and tolerability of single and multiple oral doses of aliskiren in healthy Chinese subjects: a randomized, single-blind, parallel-group, placebo-controlled study.
Hu P; Bartlett M; Karan RS; Jiang J; Zhang S; Zhang J; Howard D; Yeh CM; Al-Fayoumi S; Jarugula V; Dole WP
Clin Drug Investig; 2010; 30(4):221-8. PubMed ID: 20192280
[TBL] [Abstract][Full Text] [Related]
3. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects.
Vaidyanathan S; Maboudian M; Warren V; Yeh CM; Dieterich HA; Howard D; Dole WP
Curr Med Res Opin; 2008 Aug; 24(8):2313-26. PubMed ID: 18786303
[TBL] [Abstract][Full Text] [Related]
4. Effect of aliskiren, an oral direct renin inhibitor, on the pharmacokinetics and pharmacodynamics of a single dose of acenocoumarol in healthy volunteers.
Huang HL; Vaidyanathan S; Yeh CM; Bizot MN; Dieterich HA; Dole WP; Howard D
Curr Med Res Opin; 2008 Sep; 24(9):2449-56. PubMed ID: 18662494
[TBL] [Abstract][Full Text] [Related]
5. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.
Vaidyanathan S; Valencia J; Kemp C; Zhao C; Yeh CM; Bizot MN; Denouel J; Dieterich HA; Dole WP
Int J Clin Pract; 2006 Nov; 60(11):1343-56. PubMed ID: 17073832
[TBL] [Abstract][Full Text] [Related]
6. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjects.
Ayalasomayajula S; Tchaloyan S; Yeh CM; Bizot MN; Dieterich HA; Howard D; Dole WP
Curr Med Res Opin; 2008 Mar; 24(3):717-26. PubMed ID: 18234150
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment.
Vaidyanathan S; Bigler H; Yeh C; Bizot MN; Dieterich HA; Howard D; Dole WP
Clin Pharmacokinet; 2007; 46(8):661-75. PubMed ID: 17655373
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, safety, and tolerability of the oral Renin inhibitor aliskiren in patients with hepatic impairment.
Vaidyanathan S; Warren V; Yeh C; Bizot MN; Dieterich HA; Dole WP
J Clin Pharmacol; 2007 Feb; 47(2):192-200. PubMed ID: 17244770
[TBL] [Abstract][Full Text] [Related]
9. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus.
Zhao C; Vaidyanathan S; Yeh CM; Maboudian M; Armin Dieterich H
Clin Pharmacokinet; 2006; 45(11):1125-34. PubMed ID: 17048976
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic interaction of the direct renin inhibitor aliskiren with furosemide and extended-release isosorbide-5-mononitrate in healthy subjects.
Vaidyanathan S; Bartlett M; Dieterich HA; Yeh CM; Antunes A; Howard D; Dole WP
Cardiovasc Ther; 2008; 26(4):238-46. PubMed ID: 19035874
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of aliskiren/hydrochlorothiazide single-pill combination tablets and free combination of aliskiren and hydrochlorothiazide.
Yan JH; Jarugula V; Sabo R; Papst CC; Zhang J; Dole WP
J Clin Pharmacol; 2012 May; 52(5):645-55. PubMed ID: 21659626
[TBL] [Abstract][Full Text] [Related]
12. Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects.
Vaidyanathan S; Jermany J; Yeh C; Bizot MN; Camisasca R
Br J Clin Pharmacol; 2006 Dec; 62(6):690-8. PubMed ID: 17118124
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, safety, and tolerability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjects.
Vaidyanathan S; Reynolds C; Yeh CM; Bizot MN; Dieterich HA; Howard D; Dole WP
J Clin Pharmacol; 2007 Apr; 47(4):453-60. PubMed ID: 17389554
[TBL] [Abstract][Full Text] [Related]
14. Aliskiren: an oral direct renin inhibitor for the treatment of hypertension.
Sanoski CA
Pharmacotherapy; 2009 Feb; 29(2):193-212. PubMed ID: 19170589
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the dose--response relationship of aliskiren, a direct renin inhibitor, in an 8-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled study in adult patients with stage 1 or 2 essential hypertension.
Puig JG; Schunkert H; Taylor AA; Boye S; Jin J; Keefe DL
Clin Ther; 2009 Dec; 31(12):2839-50. PubMed ID: 20110023
[TBL] [Abstract][Full Text] [Related]
16. Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension.
Nussberger J; Gradman AH; Schmieder RE; Lins RL; Chiang Y; Prescott MF
Int J Clin Pract; 2007 Sep; 61(9):1461-8. PubMed ID: 17590217
[TBL] [Abstract][Full Text] [Related]
17. Aliskiren toxicity in juvenile rats is determined by ontogenic regulation of intestinal P-glycoprotein expression.
Hoffmann P; Beckman D; McLean LA; Yan JH
Toxicol Appl Pharmacol; 2014 Feb; 275(1):36-43. PubMed ID: 24388840
[TBL] [Abstract][Full Text] [Related]
18. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers.
Waldmeier F; Glaenzel U; Wirz B; Oberer L; Schmid D; Seiberling M; Valencia J; Riviere GJ; End P; Vaidyanathan S
Drug Metab Dispos; 2007 Aug; 35(8):1418-28. PubMed ID: 17510248
[TBL] [Abstract][Full Text] [Related]
19. Effect of verapamil on the pharmacokinetics of aliskiren in healthy participants.
Rebello S; Leon S; Hariry S; Dahlke M; Jarugula V
J Clin Pharmacol; 2011 Feb; 51(2):218-28. PubMed ID: 20413453
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of aliskiren in patients with end-stage renal disease undergoing haemodialysis.
Khadzhynov D; Slowinski T; Lieker I; Neumayer HH; Albrecht D; Streefkerk HJ; Rebello S; Peters H
Clin Pharmacokinet; 2012 Oct; 51(10):661-9. PubMed ID: 23018529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
